Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.51 |
| ▸ | STAT3 | P40763 | 13/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30782246 | 1.00 | POLB (0.51) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL30085701 | 0.89 | MAPT (0.47) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL20476536 | 0.80 | POLB (0.52) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL29426020 | 0.79 | POLB (0.51) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL31179905 | 0.79 | POLB (0.51) | POLBCTDSP1STAT3MEN1MAPT | |
| Phloyoside I SCHEMBL29426051 | 0.77 | POLB (0.55) | POLBCTDSP1STAT3MEN1MAPT | |
| Phlomiol SCHEMBL9057941 | 0.77 | POLB (0.55) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL29425813 | 0.76 | POLB (0.59) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL29426138 | 0.76 | MAPT (0.57) | POLBCTDSP1STAT3MEN1MAPT | |
| SCHEMBL29426190 | 0.75 | STAT3 (0.49) | POLBCTDSP1STAT3MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | claimed |
| WO-2022094079-A1 | METHODS OF TREATING CYSTIC FIBROSIS | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2022-05-05 | — | — | WO | claimed |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2022094079-A1 | METHODS OF TREATING CYSTIC FIBROSIS | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | CFTR, DAB2IP, CTTN | POLB 4458/4885CTDSP1 2681/4885STAT3 1831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.